Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Rosemont Pharmaceuticals Ltd. Stories

2014-02-06 08:28:48

DUBLIN, Feb. 6, 2014 /PRNewswire/ -- -- Fiscal second quarter net sales increased 11% year-over-year to a record $979 million. -- Fiscal second quarter adjusted net income increased 45% to a record $185 million, or $1.87 per diluted share. -- Fiscal second quarter GAAP net loss of $86 million or ($0.87) per diluted share, due primarily to $269 million of acquisition-related charges, including loss on extinguishment of debt. -- Record...

2013-10-31 08:33:07

-- Fiscal first quarter net sales of $933 million, up 21%. ALLEGAN, Mich., Oct. 31, 2013 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced results for its first quarter ended September 28, 2013. (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO) Perrigo's Chairman and CEO Joseph C. Papa commented, "We are off to a great start to fiscal 2014. The strength of our business model was clearly evident this quarter. Every segment experienced...

2013-02-11 08:26:43

ALLEGAN, Mich., Feb. 11, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive merger agreement and has completed the acquisition of Leeds, U.K.-based Rosemont Pharmaceuticals Ltd. ("Rosemont") for approximately £180 million or $283 million in cash. (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO) Founded in 1967, Rosemont is a specialty and generic prescription pharmaceutical company focused on the manufacturing and...